The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial-Reference-Cited by-同舟云学术

The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial

Published:2010-02-06 Issue:4 Volume:25 Page:995-1004
ISSN:0268-1161
Container-title:Human Reproduction
language:en
Short-container-title:Human Reproduction

Author:

Busso C.,Fernandez-Sanchez M.,Garcia-Velasco J. A.,Landeras J.,Ballesteros A.,Munoz E.,Gonzalez S.,Simon C.,Arce J.-C.,Pellicer A.

Publisher

Oxford University Press (OUP)

Subject

Obstetrics and Gynaecology,Rehabilitation,Reproductive Medicine

Link

http://academic.oup.com/humrep/article-pdf/25/4/995/2061005/deq005.pdf

Reference21 articles.

1. Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study

2. Dopamine Agonist Cabergoline Reduces Hemoconcentration and Ascites in Hyperstimulated Women Undergoing Assisted Reproduction

3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease

4. Prevention of OHSS – dopamine agonists

5. Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenesis and management in OHSS;Handbook of Current and Novel Protocols for the Treatment of Infertility;2024

2. Incidence and severity of ovarian hyperstimulation syndrome (OHSS) in high responders after gonadotropin-releasing hormone (GnRH) agonist trigger in “freeze-all” approach;Gynecological Endocrinology;2023-05-08

3. EGR1 Promotes Ovarian Hyperstimulation Syndrome Through Upregulation of SOX9 Expression;Cell Transplantation;2023-01

4. Ovarian hyperstimulation syndrome;Management of Infertility;2023

5. Treatment of Ovarian Hyperstimulation Syndrome;Ovarian Stimulation;2022-04-30